Hims sales dip as telehealth rivals intensify; Bristol partners with Chinese firm, other biotech updates

Hims reported lower sales this quarter, attributing the shortfall to growing competition from other telehealth providers.

Bristol announced a new partnership with Chinese drugmaker Hengrui Pharma to advance early‑stage programs, expanding its presence in China.

Rigel Pharma will commercialize the recently approved breast‑cancer therapy Veppanu under a deal that also involves Arvinas and Pfizer.

Roche secured European clearance for a blood test designed to detect early signs of Alzheimer’s disease.

BridgeBio submitted an FDA application seeking approval for encaleret, a treatment for autosomal dominant hypocalcemia type 1, a rare genetic disorder.